Inhibrx Biosciences (INBX) Net Cash Flow (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Net Cash Flow for 3 consecutive years, with -$28.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Cash Flow rose 33.99% year-over-year to -$28.9 million; the TTM figure through Dec 2025 stood at -$28.4 million (up 77.36% YoY), while the FY2025 annual figure was -$28.4 million, up 77.36% from the prior year.
• Net Cash Flow advanced to -$28.9 million in Q4 2025 per INBX's latest filing, from -$33.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $144.8 million in Q3 2023 and bottomed at -$59.4 million in Q4 2023.
• Historically, Net Cash Flow has averaged -$6.8 million across 3 years, with a median of -$29.4 million in 2025.
• Annual changes were most pronounced in 2024 — Net Cash Flow plunged 121.08% — and 2025, when it soared 351.26%.
• Inhibrx Biosciences' Net Cash Flow stood at -$59.4 million in 2023, then grew by 26.37% to -$43.7 million in 2024, then soared by 33.99% to -$28.9 million in 2025.
• Business Quant data shows INBX's Net Cash Flow at -$28.9 million in Q4 2025, -$33.5 million in Q3 2025, and -$30.0 million in Q2 2025.